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Introduction: Pleural effusions are a common clinical problem and affect about one million people in the United
States and United Kingdom each year. Over 60 causes of pleural effusion have been identified; establishing the
definitive aetiology can be difficult, and often requires invasive procedures. Guidelines state that macroscopic
examination of the fluid should be the first step in determining the aetiology of a pleural effusion. Papillary thyroid
carcinoma is an uncommon cause of malignant pleural effusion, with only 10 cases reported in the literature, their
physical characteristics and composition having been rarely described. We describe for the first time a distinctive
brown colour of the malignant effusion (despite centrifugation) from a rare case of metastatic papillary thyroid
cancer to the pleura, associated with a high pleural fluid iodine content. Such a characteristic may be useful in
expediting diagnosis of a malignant pleural effusion in the appropriate clinical context.
Case presentation: We present the case of a 71-year-old Caucasian man with metastatic papillary thyroid cancer; a
large, long-standing, right-sided pleural effusion and a 83-fold higher pleural thyroglobulin level compared to
corresponding serum, supporting this malignancy as the cause of the patient’s effusion. The pleural fluid had a
distinctive pigmentation similar to iodine-containing antiseptic preparations. Biopsy during medical thoracoscopy
confirmed metastatic papillary thyroid carcinoma. Analysis of pleural fluid showed a pleural thyroglobulin level over
80 times that of serum levels (29,000μg/L versus 350ug/L). Pleural fluid iodine content was 23,000ug/L and may
account for the fluid’s distinctive pigment, as iodine is an essential component in thyroglobulin and thyroid
hormone synthesis.
Conclusions: Pleural fluid pigmentation may aid diagnosis in the appropriate clinical setting. A distinctive iodine-
like brown colour of pleural fluid may represent elevated iodine content and should raise consideration of
metastatic thyroid cancer as a cause for a pleural effusion.
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Pleural effusion is common in clinical practice and can
be caused by over 60 pulmonary or systemic disorders.
Clinical guidelines [1] and conventional texts [2] recom-
mend that inspection of the fluid can provide useful in-
formation: pus indicates empyema, milky fluids are likely
to be chylous, blood suggests a haemothorax and food* Correspondence: gary.lee@liwa.uwa.edu.au
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distribution, and reproduction in any mediumparticles indicate oesophageal leaks or fistulae from the
gastrointestinal tract. To the best of our knowledge, a
dark brown pleural effusion has not been described.
Malignant pleural effusions are a common clinical
problem, and a wide variety of malignancies can metas-
tasise to the pleura. Papillary thyroid carcinoma is an
uncommon cause of malignant pleural effusion, with
only 10 cases in total reported in the literature [3-9],
their physical characteristics rarely documented and
their composition (for example thyroglobulin levels) sel-
dom described. Iodine is an essential element in the
pathway of hormone synthesis in the thyroid gland. Toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Chest computed tomography scan confirming a large,
right-sided pleural effusion in the setting of metastatic
papillary thyroid carcinoma, prior to drainage and pleuroscopy.
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has not previously been assayed.
We report for the first time a distinctive dark brown
pigmentation of the pleural fluid from metastatic malig-
nant papillary thyroid carcinoma, as explained by our
biochemical finding of a high iodine content in the fluid.
The pleural fluid thyroglobulin was also the highest
reported to date.
Case presentation
A 71-year-old Caucasian man diagnosed with metastatic
papillary thyroid cancer was referred to the Pleural
Clinic for management of a large right-sided effusion.
He was diagnosed with papillary thyroid cancer (PTC)
11 years prior, and was treated with total thyroidectomy
and adjuvant radio-iodine treatment. Mutation analysis
was not performed. Over the next four to six years of
follow-up, he received further radioactive iodine therapy
due to disease recurrence with rising serum thyroglobu-
lin levels. Small pulmonary metastases were first iden-
tified as fluorodeoxyglucose (FDG)-avid lesions on
positron emission tomography-computed tomography
(PET-CT) five years before this presentation, together
with right-sided pleural thickening. Since then serial
serum thyroglobulin showed continual rises from 51
to 1100ug/L over four years. The patient had iodine-
refractory disease and was enrolled in a clinical trial of
pazopanib, a multi-targeted receptor tyrosine kinase
inhibitor, two years prior to his presentation to the
Pleural Clinic. Treatment with pazopanib, significantly
reduced his thyroglobulin level to 290ug/L.
He was an ex-smoker, with a history of ischaemic
heart disease, peripheral vascular disease and asbestos
exposure.
When assessed at our Pleural Clinic, he was dyspnoeic
and had a large, right-sided pleural effusion on CT scan
(Figure 1) and ultrasound. A thoracentesis and a subse-
quent medical thoracoscopy both revealed an unusual
dark brown pleural fluid (very similar in colour to com-
monly used iodine-based antiseptic solutions) (Figure 2a),
also seen on the additional movie file (see Additional file 1),
which remained after centrifugation (Figure 2b). The fluid
was an exudate by Light’s criteria (protein 85g/L, lactate de-
hydrogenase (LDH) 712U/L) and had a pH of 7.13 and glu-
cose 0.8mmol/L. Cytological and immunohistological
features were consistent with adenocarcinoma, with posi-
tive thyroid transcription factor-1 (TTF-1) and PAX8
suggesting metastatic thyroid carcinoma. However, thyro-
globulin staining was negative, making an unequivocal diag-
nosis difficult.
Medical thoracoscopy revealed multiple areas of
tumour deposits on the parietal and visceral pleura,
clearly shown in the additional movie file (see Additional
file 1). Many of the tumour nodules had the sameunique dark brown pigmentation as the pleural fluid.
Histopathology showed papillary structures, colloid
material, psamomma bodies and adenocarcinoma cells
positive for TTF-1 and thyroglobulin, confirming a
metastatic PTC.
Pleural fluid thyroglobulin was more than 80-fold
higher than in corresponding serum (29,000 versus
350ug/L), and is the highest level yet reported. Given the
unusual colour of the fluid and its striking resemblance
to iodine solutions, we analysed the pleural fluid total
iodine content using inductively coupled plasma mass
spectrometry [10] and showed a high concentration of
23,000ug/L. Both the pleural fluid iodine and thyro-
globulin concentrations were from the extracellular
component of the fluid analysed.
The patient received a talc poudrage pleurodesis and
continued with pazopanib therapy.
Discussion
We report a case of metastatic PTC to the pleura and
describe for the first time a high iodine content of the
fluid that explains an unusual dark brown colour of the
pleural fluid not previously reported.
Papillary thyroid cancer is the most common form of
thyroid malignancy and metastatic disease tends to in-
volve local lymph nodes [11]. Distant metastases to the
lungs are uncommon; metastasis to the pleura is very
rare. In one series, only 0.6% of PTC patients developed
a malignant pleural effusion [4].
Figure 2 Distinctive dark brown pigmentation of pleural fluid during pleuroscopy and persisting post fluid centrifugation. (a) Pleural
fluid with a distinctive dark brown pigmentation visible during pleuroscopy of the patient with metastatic papillary thyroid carcinoma. The lung
remained trapped post pleuroscopy and drainage. (b) Persistence of brown pigmentation of pleural fluid post centrifugation, suggesting the
presence of a dissolved substance later confirmed to be iodine.
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first step in its analysis, and can provide clues to empy-
ema, chylous effusions, haemothorax or oesophageal
perforation. This is, however, the first report of a dis-
tinctive dark brown colour in a pleural effusion with a
corresponding high iodine content in the fluid, presum-
ably from synthesis of iodine-rich molecules by pleural
PTC deposits. Brown effusions in themselves are not
unique or pathognomic of metastatic PTC, and brown-
ish effusions, of different color intensity, can be seen
with degradation of haemoglobin, rupture of amoebic
liver abscesses and parasitic infection [12]. Similar
coloured fluid has been described in thyroid cysts but its
iodine content was not measured [13]. How often a high
iodine content and a brown effusion are present in PTC
is unknown. However, the iodine-like colour of pleural
fluid may alert clinicians to the possibility of metastatic
PTC in the investigation of pleural effusions.
Serum thyroglobulin is well established as a monitor-
ing method for disease activity in PTC [14]. In this
setting, the patient’s significantly raised pleural thyro-
globulin levels (almost two logs higher than in corre-
sponding serum) are noteworthy, and this finding has
been suggested as a potential adjunct diagnostic marker
[5]. Indeed, the pleural fluid thyroglobulin concentration
in our patient was the highest ever documented. This
may reflect the extent of pleural tumour and/or the
chronicity of the effusion. Our observation supports the
suggestion of pleural fluid thyroglobulin (or its ratio over
serum) as a potential biomarker for diagnosis, and it
may reflect disease burden - though these suggestions
require formal testing.
Conclusions
This case is the first to report high iodine content and
an associated distinctive brown colour in the malignant
effusion fluid from metastatic PTC. The usefulness ofthese findings in aiding diagnosis of metastatic pleural
disease from PTC deserves investigation. In the mean-
time, a dark brown iodine-coloured effusion should raise
the consideration of metastatic thyroid diseases.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Additional file
Additional file 1: Right pleural space during medical pleuroscopy.
The distinctive pleural fluid colour is demonstrated and lesions confirmed
as metastatic papillary thyroid carcinoma shown on the parietal and
visceral pleura.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AR analysed and interpreted the patient data regarding the pleural disease
and fluid characteristics, reviewed the literature, and provided a major
contribution to the writing of the manuscript. EML provided clinical and
technical advice and performed the pleural fluid chemical analysis. MM
provided clinical advice and reviewed the manuscript. YCGL performed the
pleursocopy, edited the manuscript and advised on all aspects of the case
report. All authors read and approved the final manuscript.
Author details
1Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Hospital
Avenue, Nedlands, Perth, WA 6009, Australia. 2Department of Clinical
Biochemistry, PathWest Laboratory Medicine WA, QEII Medical Centre,
Hospital Avenue, Nedlands, Perth, WA 6009, Australia. 3Department of
Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands,
Perth, WA 6009, Australia. 4School of Medicine and Pharmacology, University
of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.
5Centre for Asthma, Allergy & Respiratory Research, University of Western
Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.
Received: 21 January 2013 Accepted: 15 April 2013
Published: 31 May 2013
Rosenstengel et al. Journal of Medical Case Reports 2013, 7:147 Page 4 of 4
http://www.jmedicalcasereports.com/content/7/1/147References
1. Hooper C, Lee YCG, Maskell N: Investigation of a unilateral pleural
effusion in adults: British Thoracic Society pleural disease guideline 2010.
Thorax 2010, 2:ii4–ii17.
2. Light RW, Lee YCG (Eds): Textbook of Pleural Diseases. 2nd edition. London:
Hodder Arnold; 2008.
3. Jeon MJ, Yim JH, Kim EY, Kim YG, Kim TY, Kim WB, Shong YK: Four cases of
malignant pleural effusion in patients with papillary thyroid carcinoma.
Endocrinol Metab 2011, 26:330–334.
4. Vassilopoulou-Sellin R, Sneige N: Pleural effusion in patients with
differentiated papillary thyroid cancer. South Med J 1994, 87:1111–1116.
5. Mundi MS, Lopresti J, Lee WA: Utility of pleural fluid Thyroglobulin (Tg)
measurement in malignant pleural effusion from metastatic papillary thyroid
cancer (MPTC), Proceedings of the Endocrine Society 90th Annual Meeting.
San Francisco; 2008.
6. Kim JY, Park DW, Na JO, Hwang BY, Kim DL, Shin DH, Kim SG, Choi KM, Baik
SH, Choi DS, Cho SJ, Kim NH: A case of malignant pleural effusion with
pleural metastasis in a patient with papillary thyroid carcinoma. J Korean
Soc Endocrinol 2002, 17:269–274.
7. Krishnamurthy A, Siddappa KT: Papillary thyroid carcinoma with malignant
pleural effusion: Dilemma of etiology. Int J Head Neck Surg 2010, 1:117–
119.
8. Mundathaje U, Murali G, Ali H, Goldberg S: Papillary carcinoma of thyroid
recurring as pleural effusion 26 years after curative therapy. Chest 2006,
130:331S.
9. Vernon A, Sheeler L, Biscotti C, Stoller J: Pleural effusion resulting from
metastatic papillary carcinoma of the thyroid. Chest 1992, 101:1448–1450.
10. Pino S, Fang S, Braverman LE: Ammonium persulfate: a safe alternative
reagent for measuring urinary iodide. Clin Chem 1996, 42:239–243.
11. Sclumberger M: Papillary and follicular thyroid carcinoma. N Eng J Med
1998, 338:297–306.
12. Yokoyama T, Hirokawa M, Imamura Y, Aizawa H: Respiratory failure caused
by intrathoracic amoebiasis. Infect Drug Resist 2010, 3:1–4.
13. Demirci H, Erdamar H, Bukan N, Dikmen K, Karakoc A, Arslan M:
Biochemical and hormonal composition, cytological examination of
thyroid cyst fluid, and comparison according to gender and color of cyst
fluid. Clin Chem Lab Med 2007, 45:1517–1522.
14. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L,
Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah
BM, Ladenson PW, Pinchera A: A consensus report of the role of serum
thyroglobulin as a monitoring method for low-risk patients with
papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88:1433–1441.
doi:10.1186/1752-1947-7-147
Cite this article as: Rosenstengel et al.: A distinctive colour associated
with high iodine content in malignant pleural effusion from metastatic
papillary thyroid cancer: a case report. Journal of Medical Case Reports
2013 7:147.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
